Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Terminal erythroid differentiation as a biomarker for prognosis and treatment, and therapeutic target in myeloid malignancies

Terminal erythroid differentiation as a biomarker for prognosis and treatment, and therapeutic target in myeloid malignancies

US Patent 11186877 · Granted Nov 30, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents2023
Compositions and methods for inhibition of lineage specific antigens2021
Compositions and methods for inhibition of lineage specific antigens2020
Compositions and methods for inhibition of lineage specific antigens2020
Compositions and methods for inhibition of lineage specific antigens2020
Methods and compositions for treatment of cancer2020
Compositions and methods for inhibition of lineage specific antigens2018
Retrovirus associated with myelodysplastic syndromes and uses thereof2006
Compositions and diagnostic kits for identifying alveolar rhabdomyosarcoma1997